US12420098B1ActiveUtility

Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods

77
Assignee: NEVRO CORPPriority: Jun 22, 2012Filed: Jan 20, 2022Granted: Sep 23, 2025
Est. expiryJun 22, 2032(~5.9 yrs left)· nominal 20-yr term from priority
Inventors:Bradford Evan Gliner
A61N 1/36121A61N 1/36062A61N 1/36071A61N 1/36171A61N 1/36139
77
PatentIndex Score
0
Cited by
1,179
References
38
Claims

Abstract

Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods. A method for treating a patient in accordance with a particular embodiment includes selecting a neural modulation site to include a neural population of the patient's spinal cord, and selecting parameters of a neural modulation signal to at least reduce an autonomic system deficit in the patient.

Claims

exact text as granted — not AI-modified
I claim: 
     
       1. A method for regulating a patient's blood glucose levels, comprising:
 programming a signal generator to deliver a non-paresthesia producing electrical signal to the patient's spinal cord via at least one implanted signal delivery device, 
 wherein the non-paresthesia producing electrical signal regulates the patient's blood glucose levels by modulating neurons of the patient's autonomic nervous system. 
 
     
     
       2. The method of  claim 1  wherein modulating neurons of the patient's autonomic nervous system includes normalizing a combined effect of the patient's sympathetic and parasympathetic systems to regulate the patient's blood glucose levels. 
     
     
       3. The method of  claim 1  wherein the non-paresthesia producing electrical signal modulates neurons of the patient's sympathetic nervous system. 
     
     
       4. The method of  claim 3  wherein the non-paresthesia producing electrical signal inhibits neurons of the patient's sympathetic nervous system. 
     
     
       5. The method of  claim 1  wherein modulating neurons of the patient's autonomic nervous system includes reducing or modifying organ dysfunction in the patient to regulate the patient's blood glucose levels. 
     
     
       6. The method of  claim 5  wherein the implanted signal delivery device is positioned at a vertebral level associated with an organ responsible for the organ dysfunction in the patient. 
     
     
       7. The method of  claim 6  wherein the vertebral level is an upper thoracic vertebral level. 
     
     
       8. The method of  claim 6  wherein the vertebral level is a cervical vertebral level. 
     
     
       9. The method of  claim 1  wherein the at least one implanted signal delivery device is positioned in an epidural space within the patient's spinal cord region. 
     
     
       10. The method of  claim 1  wherein the non-paresthesia producing electrical signal has a frequency in a frequency range of from 1.5 kHz to 100 KHz. 
     
     
       11. The method of  claim 1  wherein the non-paresthesia producing electrical signal has a frequency in a frequency range of from 5 KHz to 50 KHz. 
     
     
       12. The method of  claim 1  wherein the non-paresthesia producing electrical signal has a frequency in a frequency range of from 5 kHz to 25 KHz. 
     
     
       13. The method of  claim 1  wherein the non-paresthesia producing electrical signal has a frequency of 10 kHz. 
     
     
       14. The method of  claim 1  wherein the non-paresthesia producing electrical signal has an amplitude in an amplitude range of from 0.1 mA to 20 mA. 
     
     
       15. The method of  claim 1  wherein the non-paresthesia producing electrical signal has a pulse width in a pulse width range of from 25 microseconds to 166 microseconds. 
     
     
       16. The method of  claim 1  wherein the non-paresthesia producing electrical signal has (i) a frequency in a frequency range of from 1.5 kHz to 100 KHz, (ii) an amplitude in an amplitude range of from 0.1 mA to 20 mA, and (iii) a pulse width in a pulse width range of from 25 microseconds to 166 microseconds. 
     
     
       17. The method of  claim 1  wherein programming the implantable signal generator includes programming the implantable signal generator to deliver the non-paresthesia producing electrical signal in accordance with a duty cycle. 
     
     
       18. The method of  claim 1  wherein programming the implantable signal generator is done in response to the patient having a disorder characterized by abnormal regulation of blood glucose levels. 
     
     
       19. The method of  claim 1  wherein the signal generator is implantable. 
     
     
       20. A method for normalizing a patient's diabetic response, comprising:
 programming a signal generator to deliver a non-paresthesia producing electrical signal to the patient's spinal cord via at least one implanted signal delivery device, 
 wherein the non-paresthesia producing electrical signal normalizes the patient's diabetic response by modulating neurons of the patient's autonomic nervous system. 
 
     
     
       21. The method of  claim 20  wherein modulating neurons of the patient's autonomic nervous system includes normalizing a combined effect of the patient's sympathetic and parasympathetic systems to normalize the patient's diabetic response. 
     
     
       22. The method of  claim 20  wherein the non-paresthesia producing electrical signal modulates neurons of the patient's sympathetic nervous system. 
     
     
       23. The method of  claim 22  wherein the non-paresthesia producing electrical signal inhibits neurons of the patient's sympathetic nervous system. 
     
     
       24. The method of  claim 22  wherein modulating neurons of the patient's autonomic nervous system includes reducing or modifying organ dysfunction in the patient to normalize the patient's diabetic response. 
     
     
       25. The method of  claim 24  wherein the implanted signal delivery device is positioned at a vertebral level associated with an organ responsible for the organ dysfunction in patient. 
     
     
       26. The method of  claim 25  wherein the vertebral level is an upper thoracic vertebral level. 
     
     
       27. The method of  claim 25  wherein the vertebral level is a cervical vertebral level. 
     
     
       28. The method of  claim 20  wherein the at least one implanted signal delivery device is positioned in an epidural space within the patient's spinal cord region. 
     
     
       29. The method of  claim 20  wherein the non-paresthesia producing electrical signal has a frequency in a frequency range of from 1.5 kHz to 100 kHz. 
     
     
       30. The method of  claim 20  wherein the non-paresthesia producing electrical signal has a frequency in a frequency range of from 5 kHz to 50 KHz. 
     
     
       31. The method of  claim 20  wherein the non-paresthesia producing electrical signal has a frequency in a frequency range of from 5 kHz to 25 kHz. 
     
     
       32. The method of  claim 20  wherein the non-paresthesia producing electrical signal has a frequency of 10 KHz. 
     
     
       33. The method of  claim 20  wherein the non-paresthesia producing electrical signal has an amplitude in an amplitude range of from 0.1 mA to 20 mA. 
     
     
       34. The method of  claim 20  wherein the non-paresthesia producing electrical signal has a pulse width in a pulse width range of from 25 microseconds to 166 microseconds. 
     
     
       35. The method of  claim 20  wherein the non-paresthesia producing electrical signal has (i) a frequency in a frequency range of from 1.5 kHz to 100 kHz, (ii) an amplitude in an amplitude range of from 0.1 mA to 20 mA, and (iii) a pulse width in a pulse width range of from 25 microseconds to 166 microseconds. 
     
     
       36. The method of  claim 20  wherein programming the implantable signal generator includes programming the implantable signal generator to deliver the non-paresthesia producing electrical signal in accordance with a duty cycle. 
     
     
       37. The method of  claim 20  wherein programming the implantable signal generator is done in response to the patient having a disorder characterized by an abnormal diabetic response. 
     
     
       38. The method of  claim 20  wherein the signal generator is implantable.

Join the waitlist — get patent alerts

Track US12420098B1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.